CatalystMarker
← board

LEEEF

distress 2/10 · well-funded / low risk
$0.20-5%today-18% from 52w high
leefbrands.com81 employeesVancouver, BCDrug Manufacturers - Specialty & Generic
Revenue
pre-revenue
Liquidity
$6M
Runway
Shares 1y
+5%

Price & events

+54.2% over 6M
$0.11$0.16$0.22Jan 26Apr 26Jul 262.1Mdilution: S-1 shelf_registration (2026-07-09)financing: 8-K private_placement (2026-06-02)financing: 8-K private_placement (2026-05-05)financing: 8-K private_placement (2026-04-20)catalyst: N/A (2026-04-30) — click to open
CatalystRating changeDilutionFinancingdashed = today
-5.2%
1D
-4.3%
1W
+15.4%
1M
+15.4%
3M
+54.2%
6M
+11.6%
1Y
+2144.4%
2Y
-15.8%
5Y
-57.9%
All

Overview

Market Cap
$56.63M
Volume
259.20K
52 Week Range
$0.11 – $0.24
Total Shares
280.36M
Float Shares
244.00M
% Held by Insiders
24.10%
% Held by Institutions
0.45%
RVOL
0.61x
Beta
0.31

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 2

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 280,358,364 · 0 offerings/1y · 3 PIPEs
  • 2026-07-09S-1shelf_registration
  • 2026-06-028-Kprivate_placement
  • 2026-05-058-Kprivate_placement
  • 2026-04-208-Kprivate_placement
  • 2025-12-23S-1/Ashelf_registration
  • 2025-11-07S-1/Ashelf_registration
  • 2025-08-26S-1shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.